Please check your internet connection and try again.
# Sompraz HP (Omeprazole)
## Overview
Sompraz HP is a combination product containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*). Lansoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics.
## Primary Indications
* Eradication of *Helicobacter pylori* (*H. pylori*) infection in patients with peptic ulcer disease.
## Adult Dosing
The standard regimen is Sompraz HP taken twice daily for 14 days. Each dose pack typically contains:
* Lansoprazole 30 mg capsules (2 capsules per dose)
* Amoxicillin 500 mg capsules (2 capsules per dose)
* Clarithromycin 250 mg tablets (1 tablet per dose)
**Therefore, per dose, the patient takes:**
* Lansoprazole 60 mg
* Amoxicillin 1000 mg
* Clarithromycin 250 mg
This is administered **twice daily for 14 days**.
## Pediatric Dosing
Dosing for Sompraz HP in pediatric patients is not established. Treatment should be guided by expert opinion or specialist consultation, considering the individual components' pediatric dosing if separated.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment for lansoprazole is recommended in mild to moderate renal impairment. However, caution is advised. Clarithromycin should be reduced by 50% in severe renal impairment (creatinine clearance <30 mL/min). Amoxicillin dose adjustment may be necessary in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment for lansoprazole is recommended in mild to moderate hepatic impairment. Clarithromycin dose should be reduced by 50% in moderate to severe hepatic impairment.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of allergic reactions to penicillins, cephalosporins, or macrolides.
* Concomitant use with rifampin, ergot derivatives, cisapride, pimozide, or astemizole (due to clarithromycin).
* Electrolyte abnormalities, particularly hypokalemia or hypomagnesemia, prior to treatment with PPIs.
* Myasthenia gravis (clarithromycin).
## Adverse Effects
* **Common:** Diarrhea, headache, taste disturbance, nausea, abdominal pain, constipation, rash, dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea, anaphylaxis, severe skin reactions (e.g., Stevens-Johnson syndrome), liver dysfunction, QT prolongation (clarithromycin), interstitial nephritis (lansoprazole), tendon rupture (fluoroquinolones - *note: this is a class effect and not directly associated with amoxicillin or clarithromycin, but important PPI consideration*), *C. pylori* resistance.
## Key Drug Interactions
* **Lansoprazole:** May decrease the absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, iron salts, vitamin B12). May increase levels of drugs metabolized by CYP2C19 and CYP3A4 (e.g., warfarin, diazepam, phenytoin, methotrexate).
* **Clarithromycin:** Potent inhibitor of CYP3A4. Significant interactions with statins (increased risk of myopathy), warfarin, theophylline, carbamazepine, cyclosporine, tacrolimus, digoxin, colchicine, and certain anticoagulants (e.g., dabigatran, rivaroxaban). Increased risk of QT prolongation with other QT-prolonging agents.
* **Amoxicillin:** May decrease the efficacy of oral contraceptives. Probenecid decreases renal excretion of amoxicillin.
## Monitoring
* **H. pylori Eradication:** Urea breath test, stool antigen test, or endoscopy with biopsy 4-6 weeks after completion of therapy.
* **Electrolytes:** Baseline and periodically, especially in patients with risk factors for hypokalemia or hypomagnesemia, during prolonged PPI therapy.
* **Liver Function Tests:** Periodically, especially with prolonged clarithromycin use or pre-existing liver disease.
* **Renal Function:** Monitor in patients with renal impairment.
## Clinical Pearls
* Administer lansoprazole capsules as whole, do not crush or chew.
* Ensure patients complete the full 14-day course to maximize eradication rates and minimize resistance development.
* Advise patients to report any new or worsening diarrhea, severe abdominal pain, or signs of allergic reaction immediately.
* Consider alternative regimens if there is a known local resistance pattern to clarithromycin.
* PPIs can mask symptoms of underlying malignancy, particularly in the stomach.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions. Local protocols may vary.
